Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 18;14(14):3488.
doi: 10.3390/cancers14143488.

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review

Elizabeth Katherine Anna Triumbari  1 , David Morland  1   2   3   4 , Riccardo Laudicella  5 , Matteo Bauckneht  6   7 , Domenico Albano  8   9 , Salvatore Annunziata  1
Affiliations
Review

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review

Elizabeth Katherine Anna Triumbari et al. Cancers (Basel). .

Abstract

Objective: Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging modality since then. Our scope was to assess current clinical applications of immuno-PET in patients with lymphoma. Therefore, a systematic review of the published literature was performed. Methods: PubMed/Medline and Scopus databases were independently searched by two nuclear medicine physicians, to identify studies describing the clinical use of immuno-PET in patients with lymphoma. Methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies criteria. The studies were then analyzed concerning the molecular target of interest. Results: The initial search yielded 1407 articles. After elimination of duplicates, 1339 titles/abstracts were evaluated. Only two articles were found to comply with the inclusion criteria and two more were found during the cross-reference check. Among the four included articles, three described the use of 89Zr-labelled antibodies targeting CD20+ relapsed/refractory B-cell lymphomas and one concerned the use of 68Ga-labelled mAb targeting CXCR4 in patients with non-Hodgkin lymphomas. Conclusions: Very limited literature data are currently available on the clinical use of iPET in patients with lymphoma. This technique is encountering obstacles in its wider use, possibly because of the need of specific facilities, unfavorable dosimetry, and unclear correlation of immuno-tracer biodistribution with patients' clinical and tumors' molecular characteristics. However, iPET may represent a useful tool to non-invasively visualize the heterogenous individual immunological environment, thus potentially guiding treatment-planning in lymphoma patients, and hence deserves further exploitation.

Keywords: 68Ga-pentixafor; 89Zr; human; immuno-PET; lymphoma; systematic review.

PubMed Disclaimer

Conflict of interest statement

S.A. and E.K.A.T. are funded by the Italian Ministry of Health (GR-2019-12370372). All other authors have no competing financial or non-financial interests to disclose.

Figures

Figure 1
Figure 1
Flowchart of the literature search and article selection.
See this image and copyright information in PMC

References

    1. Dun Y., Huang G., Liu J., Wei W. ImmunoPET Imaging of Hematological Malignancies: From Preclinical Promise to Clinical Reality. Drug Discov. Today. 2021;27:1196–1203. doi: 10.1016/j.drudis.2021.11.019. - DOI - PubMed
    1. Wei W., Rosenkrans Z.T., Liu J., Huang G., Luo Q.-Y., Cai W. ImmunoPET: Concept, Design, and Applications. Chem. Rev. 2020;120:3787–3851. doi: 10.1021/acs.chemrev.9b00738. - DOI - PMC - PubMed
    1. Wu A.M., Pandit-Taskar N. ImmunoPET: Harnessing Antibodies for Imaging Immune Cells. Mol. Imaging Biol. 2022;24:181–197. doi: 10.1007/s11307-021-01652-7. - DOI - PubMed
    1. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The Immune Contexture in Human Tumours: Impact on Clinical Outcome. Nat. Rev. Cancer. 2012;12:298–306. doi: 10.1038/nrc3245. - DOI - PubMed
    1. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., et al. Towards the Introduction of the ‘Immunoscore’ in the Classification of Malignant Tumours. J. Pathol. 2014;232:199–209. doi: 10.1002/path.4287. - DOI - PMC - PubMed

LinkOut - more resources